78 results
Page 3 of 4
8-K
EX-99.1
cfvgpqnv56uwqyzy6p4
13 Apr 20
ENDRA Life Sciences Announces Cash Strategy and Business Update in Response to COVID-19
4:29pm
8-K
EX-1.1
v08 9hawbn1
27 Mar 20
Entry into a Material Definitive Agreement
5:19pm
424B5
pk9wg
27 Mar 20
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
okuji24v
10 Mar 20
ENDRA Life Sciences Receives CE Mark for its TAEUS® Clinical Product Targeting Non-Alcoholic Fatty Liver Disease
8:02am
424B3
oj8iimkx4of691kzln
28 Jan 20
Prospectus supplement
4:59pm
8-K
EX-10.1
n9qi5
26 Dec 19
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
8exr0di8
11 Dec 19
ENDRA Life Sciences Completes $8.1 Million Private Placement
5:14pm
424B7
nh8ijsyfblw n8y8b
16 Sep 19
Prospectus with selling stockholder info
4:10pm
8-K
EX-10.1
uttk8p8ojpww1eegum4
29 Jul 19
ENDRA Life Sciences Completes Private Placement of $2.8 Million of Convertible Secured Notes and Warrants
8:40am
424B3
nd89e aps531eglm
12 Feb 19
Prospectus supplement
12:00am